Evidence map›Paper›PMID 37496101›Full record

ArticleBMC rheumatology2023

Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset.

Pramod Chebbi, Vineeta Shobha, Vijay K Rao, Vikram Haridas, Ramya Janardana, Benzeeta Pinto, Sharath Kumar, Abhishek Patil, Roopa Tekkatte, Manasa Salanke and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Pramod ChebbiDepartment of Rheumatology, SDMCMSH, SDM University Dharwad, Dharwad, India.
Vineeta ShobhaDepartment of Clinical Immunology and Rheumatology, St.John's Medical college Hospital, Sarjapur Road, Bengaluru, 560034, India. vineeta.s@stjohns.in.
Vijay K RaoDepartment of Rheumatology, Manipal Hospital, Bengaluru, India.
Vikram HaridasArthritis Superspeciality Center, Hubli, India.
Ramya JanardanaDepartment of Clinical Immunology and Rheumatology, St.John's Medical college Hospital, Sarjapur Road, Bengaluru, 560034, India.
Benzeeta PintoDepartment of Clinical Immunology and Rheumatology, St.John's Medical college Hospital, Sarjapur Road, Bengaluru, 560034, India.
Sharath KumarOPTIMA Rheumatology & Arthritis clinic, Bengaluru, India.
Abhishek PatilDepartment of Rheumatology, Manipal Hospital, Bengaluru, India.
Roopa TekkatteAster RV hospital, Bengaluru, India.
Manasa SalankeChanRe Rheumatology and Immunology Centre, Bangalore, India.
K M MahendranathSamarpan Health center, Bangalore, India.
St.John's Medical College Hospital · INManipal Hospital · INAster Medcity · INNethradhama Superspeciality Eye Hospital · INShri Dharmasthala Manjunatheshwara University

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib.

methodsThis is a non-interventional, cross-sectional, questionnaire based telephonic study which included consecutive AIRD patients on tofacitinib co-treatment. Data related to the AIRD subset, disease modifying anti rheumatic drugs(DMARDs) including glucocorticoids and comorbidities, was collected from 7 rheumatology centers across Karnataka during the second wave of COVID-19 pandemic. The information about COVID-19 occurrence and COVID-19 vaccination was recorded.

resultsDuring the study period (Jun-July 2021), 335 AIRD patients (80.6% female) on treatment with tofacitinib were included. The mean duration of tofacitinib use was 3.4+/-3.1months. Thirty-six(10.75%) patients developed COVID-19. Diabetes mellitus (p = 0.04 (OR 2.60 (1.13-5.99)) was identified as a risk factor for COVID-19 in our cohort. Almost half of our cohort was COVID-19 vaccinated with at least one dose, with resultant decline in incidence of COVID-19(OR 0.15 (0.06-0.39) among the vaccinated. Recovery amongst COVID-19 infection group was 91.2%.

conclusionsThe subset of AIRD patients who were on treatment with tofacitinib were found to have a higher rate of COVID-19 infection as compared to our KRACC cohort. Pre-existing comorbidity of diabetes mellitus was the significant risk factor in our cohort. This subset of the KRACC cohort shows RA patients had a lesser infection and PsA patients had a higher infection.

Indexed as

Autoimmune rheumatic diseasesConcomitant tofacitinib treatmentCovid-19SARS-CoV-2 infection

Identifiers

PMID37496101
PMCPMC10369741
OpenAlexW4385274084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.